• Dong-Hoon Kang, Joo-Young Na, Jun-Ho Yang, Seong-Ho Moon, Sung-Hwan Kim, Jae-Jun Jung, Ho-Jeong Cha, Jong-Hwa Ahn, Yong-Whi Park, Sang-Yeong Cho, Ho-Kyung Yu, Soo-Hee Lee, Mi-Yeong Park, Jong-Woo Kim, and Joung-Hun Byun.
• Department of Thoracic and Cardiovascular Surgery, Gyeongsang National University College of Medicine, Gyeongsang National University Changwon Hospital, 11, Samjeongja-ro, Seongsan-gu, Changwon 51472, Korea.
• Medicina (Kaunas). 2022 Mar 20; 58 (3).

AbstractA 48-year-old female patient underwent a heart transplantation for acute fulminant myocarditis, following heterologous vaccination with the ChAdOx1 nCoV-19 and Pfizer-BioNTech COVID-19. She had no history of severe acute respiratory syndrome coronavirus-2 infection. She did not exhibit clinical signs or have laboratory findings of concomitant infection before or after vaccination. Heart transplantation was performed because her heart failed to recover with venoarterial extracorporeal oxygenation support. Organ autopsy revealed giant cell myocarditis, possibly related to the vaccines. Clinicians may have to consider the possibility of the development of giant cell myocarditis, especially in patients with rapidly deteriorating cardiac function and myocarditis symptoms after COVID-19 vaccination.

14 keywords...

hide…